Provided herein in some aspects are methods, compositions, kits, and systems for performing multiplexed single-cell analysis on an in situ platform, providing alternatives which have a higher cell throughput and/or lower cost per cell compared to current single-cell analysis techniques. In some embodiments, the methods disclosed herein comprise using labeling agents that comprise sample-specific barcodes and/or cell feature specific barcodes (e.g., analyte specific barcodes) to label single-cell populations, immobilizing the labeled cells, and performing in situ detection of the labeling agents and/or other features including cellular analytes of the labeled cells.

Methods, devices, and systems for analyzing biological samples are provided. A biological sample may be analyzed for the presence of an analyte by an initial assay, and the performance of, or method of performance of, a subsequent assay may be contingent upon the results of the initial assay. For example, the following may be contingent on the results of a prior assay: whether or not a subsequent assay is performed; which subsequent assay is performed; the method of performing a subsequent assay; the order of performance of a sequence of subsequent assays; the steps, or order of steps, performed in a subsequent assay; the timing of the performance of a subsequent assay; the choice of a reagent used in a subsequent assay; the detection method used in a subsequent assay; and other particulars of assays may be contingent on the results of a prior assay.

Methods of producing a plurality of distinguishably fluorescently barcoded particle, e.g., cellular, bead, etc., samples, e.g., for use in the multiplex flow cytometric workflows, are provided. Aspects of the methods include: providing a plurality of particle, e.g., cellular, bead, etc., samples; and labeling different particle, e.g., cellular, bead, etc., samples of the plurality with unique fluorescent barcodes, wherein a given fluorescent barcode comprises one or more fluorescently labeled specific binding members that specifically bind to a particle marker. Also provided are compositions for practicing methods of the invention.

Methods and kits for isolating at least one of a plurality of single circulating trophoblasts (cTBs) and a plurality of clustered circulating trophoblasts (cTBs) from a blood sample and determining whether a subject has a placenta accrete spectrum (PAS) disorders.

Disclosed is a method for correlating at least one amino acid sequence from an antibody isolated from human or animal blood with at least one DNA sequence corresponding to the antibody in the immunorepertoire of the human or animal. The method also provides a means for pairing heavy and light chains to produce synthesized monoclonal antibodies.

The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and/or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver/bone/kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141.

Single domain antibody/polymeric fluorescent tandem dye conjugates are provided. Aspects of the provided conjugates include: a single domain antibody having one or more polymeric tandem fluorescent dyes conjugated thereto. In some instances, the polymeric tandem fluorescent dye includes: (i) a polymeric backbone made up of non-conjugated repeat units; (ii) a plurality of pendant donor chromophore groups each independently linked to a non-conjugated repeat unit of the polymeric backbone; and (iii) one or more pendant acceptor fluorophores linked to a non-conjugated repeat unit of the polymeric backbone, wherein pendant donor and acceptor fluorophores are in energy transfer relationship. Also provided are methods of using the conjugates, e.g., in methods of evaluating a sample for the presence of a target analyte, and kits comprising the conjugates that find use in embodiments of the methods.

Presented herein are methods of evaluating cellular activity by: placing a cell population on an area; assaying for a dynamic behavior of the cell population as a function of time; identifying cell(s) of interest based on the dynamic behavior; characterizing a molecular profile of the cell(s); and correlating the obtained information. The assayed dynamic behavior can include cellular activation, cellular inhibition, cellular interaction, protein expression, protein secretion, cellular proliferation, changes in cellular morphology, motility, cell death, cell cytotoxicity, cell lysis, and combinations thereof. Sensors associated with the area may be utilized to facilitate assaying. Molecular profiles of the cell(s) can then be characterized by various methods, such as DNA analysis, RNA analysis, and protein analysis. The dynamic behavior and molecular profile can then be correlated for various purposes, such as predicting clinical outcome of a treatment, screening cells, facilitating a treatment, diagnosing a disease, and monitoring cellular activity.

A method is described for using live mesenchymal stromal cells (MSCs) in a way which allows for identification of patients likely to respond to immunosuppressive treatment using MSCs. The method involves contacting a sample from said patient with live MSCs in vitro, and determining whether the sample is able to induce at least some apoptosis to occur in live MSCs in vitro, or detection of elevated levels of prostaglandin E2 (PGE2). The ability of the sample to induce said apoptosis and/or elevated levels of PGE2 is indicative of responsiveness of said patient to said immunosuppressive treatment and/or indicative of fitness to recover. Also provided are apoptotic MSCs for use in the treatment of immune-mediated disease or conditions, such as allo-immune or autoimmune disease, or for the prevention or treatment of rejection of a transplanted organ; or in regenerative medicine to stimulate tissue repair. Methods for preparing pharmaceutical compositions comprising the apoptotic MSCs are also described and claimed.

The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.